// App-Quantinova.ai

42 : Pathological heterogeneity after trastuzumab and combination chemotherapy in HER2+ gastroesophageal adenocarcinoma xenograft.

Researchers

Presenter

  • Connie Yip

Principal Investigators

  • Amanda Weeks

  • Gary J. R. Cook

  • Karen Shaw

  • Muhammad Siddique

  • David B. Landau

  • Vicky Goh

Medical Centers

  • Division of Imaging Sciences and Biomedical Engineering, King's College London, London, United Kingdom

  • Division of Imaging Sciences and Biomedical Engineering, King's College London, London, United Kingdom

  • Guy's And St Thomas NHS Foundation Trust, London, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Gastroesophageal junction (GEJ) adenocarcinoma

Biomarkers

  • Microvessel density

  • Cluster of Differentiation 34

  • erb-b2 receptor tyrosine kinase 2

Drug/Treatment

  • Pimonidazole

  • Trastuzumab

  • Cisplatin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved